Acadia Q4 net income $143.7M; FY2024 revenue $957.8M (+32%); guides FY2025 rev $1.03-1.095B

ACADIA PHARMACEUTICALS INC

2024-FY EPS reported $1.36 revenue$957,797,000

FY2024 total net product sales $957.8M, up 32% YoY; NUPLAZID $609.4M (+11%), DAYBUE $348.4M (+97%).
Q4 net income $143.7M ($0.86 EPS) vs $45.8M ($0.28 EPS) in Q4 2023; includes $146.5M PRV sale gain.
FY2024 net income $226.5M ($1.37 EPS) vs net loss of $61.3M ($0.37 loss per share) in FY2023.
FY2025 guidance: total revenue $1.03-1.095B; NUPLAZID $650-690M; DAYBUE $380-405M; R&D $310-330M; SG&A $535-565M.
Cash and investments $756.0M at Dec 31, 2024, up from $438.9M; EMA submission for trofinetide completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.